Agenus | AGEN - Debt


Agenus reported $35.54M in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Agenus USD 35.54M 2.34M Mar/2025
Amgen USD 54.59B 1.62B Sep/2025
AstraZeneca USD 32.63B 207M Sep/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Celldex Therapeutics USD 2.62M 410K Sep/2025
CSL USD 11.96B 219M Dec/2024
Eli Lilly USD 42.51B 2.6B Sep/2025
Gilead Sciences USD 24.94B 5M Sep/2025
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Glaxosmithkline GBP 17.75B 396M Sep/2025
Incyte USD 40.41M 855K Dec/2025
Intrexon USD 0 13.82M Jun/2024
J&J USD 47.93B 2.14B Dec/2025
Jiangsu Hengrui CNY 91.43M 17.24M Jun/2025
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
MacroGenics USD 37.01M 238K Sep/2025
Merck EUR 12.1B 2.7B Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Northwest Biotherapeutics USD 32.94M 6.93M Sep/2023
Novartis USD 32.64B 1.37B Jun/2025
Novavax USD 233.31M 4.23M Sep/2024
Pfizer USD 60.85B 78M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Veracyte USD 40.45M 10.19M Sep/2025